News
06-26-2018, 07:13 AM
A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.
More... (https://www.news-medical.net/news/20180626/Phase-1-clinical-trial-of-poliovirus-therapy-shows-long-term-survival-benefit-for-recurrent-glioblastoma.aspx)
More... (https://www.news-medical.net/news/20180626/Phase-1-clinical-trial-of-poliovirus-therapy-shows-long-term-survival-benefit-for-recurrent-glioblastoma.aspx)